A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.

Pfizer

Status: Withdrawn

Conditions: Carcinoma, Non-Small-Cell Lung

Treatments: Drug: dacomitnib

Study type: Observational

Funder types: Industry

Identifiers

NCT06075615

A7471072

NCT06075615 (Registry Identifier)

Details and patient eligibility

About

The purpose of this study is to learn about dacomitinib for the possible treatment of lung cancer which has spread to other parts of the body.

This study is seeking participants who:

• have lung cancer that has reached at least the brain.
• have a type of gene called epidermoid growth factor receptor. A gene is a part of your DNA that has instructions for making things your body needs to work.
• have not received any treatment before.

All participants in this study will receive dacomitnib 1 time a day. Dacomitinib is a tablet that is taken by mouth at home. They can continue to take dacomitnib until their cancer is no longer responding. The study will look at the experiences of people receiving the study medicine. This will help to see if the study medicine is safe and effective.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• at least 18 years old
• confirmed diagnosis of EGFR mutation-positive NSCLC
• at least one measurable intracranial metastasis
• ECOG-PS of 0, 1 or 2
• dacomitinib as first-line treatment for advanced NSCLC
• Evidence of a personally signed and dated informed consent document (ICD)

Exclusion criteria

• any anti-cancer systemic treatment within 12 months prior to index date
• currently on active investigational drug(s) treatment in other clinical studies (Phase 1-4) within 2 weeks before the current study begins and/or during study participation.

Trial design

0 participants in 1 patient group

dacomitnib

Treatment:

Drug: dacomitnib